Clinical Trial Starts for Inhaled COVID-19 Treatment

Clinical Trial Starts for Inhaled COVID-19 Treatment

A new COVID-19 treatment that is inhaled directly into the lungs is being tested in Britain.

A clinical trial of aerosolized interferon beta protein that is delivered into the patient’s body using a nebulizer began Tuesday. The drug was developed by researchers at University Hospital Southampton and produced by the biotech firm Synairgen.

According to The Week, the new drug has been shown to reduce the odds of COVID-19 patients developing severe symptoms by an impressive 80% in a phase 2 trial of 100 patients. The phase 3 trial, which begins this week, has over 600 volunteers in 20 countries, with half receiving the inhaled COVID-19 treatment and the other half getting a placebo.

Interferon beta protein is part of the immune system’s first line of defense against viruses, but COVID-19 appears to suppress its production to avoid being targeted, according to the BBC News. The new drug delivers the protein into the lungs and triggers a stronger anti-viral response even in weakened patients. In phase 2 trials, patients were two to three times more likely to regain their health to return to everyday activities when given the treatment. Hospitalization time was also reduced by a third.

The treatment was developed by the Southampton research team after it was discovered that people with chronic lung disease, such as asthma, have low levels of interferon beta. They thought that by boosting the patients’ levels of this protein, they could improve their condition. Since research has shown that COVID-19 can suppress interferon beta levels, the same treatment could help patients with the virus recover.

While the early trials have been successful, experts warn that promising treatments do not always pan out, according to The Week.

“We’ve had other drugs in similar circumstances, we’ve had hydroxychloroquine, for example,” Dr. Lamis Latif, an urgent care physician in London, told BBC News. “But again it, when that reached further trials, it wasn’t as promising as it initially made up to be.”

© 2021 NewsmaxHealth. All rights reserved.

There is no custom code to display.

Blogs

670 KBOI Guest BLOG:  Superintendent of Public Instruction Sherri Ybarra

670 KBOI Guest BLOG: Superintendent of Public Instruction Sherri Ybarra

670 KBOI Guest BLOG: Superintendent of Public Instruction Sherri Ybarra Superintendent Ybarra praises Gov. Little’s continued commitment to education Monday’s State of the State address by Gov. Brad Little offered welcome news to educators and families throughout Idaho. “Investing in Idaho’s public schools continues to be the top priority for Gov. Little, with a particular…

670 KBOI Guest BLOG:  IEA President Layne McInelly

670 KBOI Guest BLOG: IEA President Layne McInelly

670 KBOI Guest BLOG: IEA President Layne McInelly Governor’s Budget Shows Promise, but Lacks Bold Vision Needed “Governor Little’s budget proposal checks some important boxes, but it lacks the bold vision and initiative Idaho students deserve.  Idaho’s prosperous economy, a budget surplus of more than $600 million, and a growing population make this an ideal time…

Worthington BLOG: Are you part of problem?

Worthington BLOG: Are you part of problem?

By Rick Worthington 1/7/21 Are you part of problem? If you believe violence is the solution to political disagreement, you are part of the problem. If you believe rioting and looting is ok, you are part of the problem. If you hate somebody based on race or religion, you are part of the problem. If…

Worthington BLOG: The Battleground States

Worthington BLOG: The Battleground States

The Battleground States By Rick Worthington 10/12/2020   Idaho is a RED STATE. Very Red. I hereby am ready to call Idaho and it’s mere 4 electoral votes for Donald Trump and Republicans in the 2020 Presidential Election. I am not walking out on a limb, because Idaho is not a swing state, or Battleground…